John P Leach1,2, James F Martin3,4,5,6. 1. Department of Molecular Physiology and Biophysics, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA. 2. Department of Medicine, Penn Center for Pulmonary Biology, Penn Cardiovascular Institute, Penn Institute for Regenerative Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA. 3. Department of Molecular Physiology and Biophysics, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA. jfmartin@bcm.edu. 4. Cardiomyocyte Renewal Lab, Texas Heart Institute, 6770 Bertner Avenue, Houston, TX, 77030, USA. jfmartin@bcm.edu. 5. Program in Developmental Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA. jfmartin@bcm.edu. 6. Cardiovascular Research Institute, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA. jfmartin@bcm.edu.
Abstract
PURPOSE OF REVIEW: Current pharmacologic treatments for cardiovascular disease do not correct the underlying cellular defect, the loss of cardiomyocytes. With recent advancements in cardiac regenerative approaches, the induction of endogenous mature cardiomyocyte proliferation has emerged as a new possibility. Here, we review progress made toward the regeneration of cardiac tissue in the mammalian heart through the stimulation of mature cardiomyocyte renewal. RECENT FINDINGS: The targeting of several developmental and signaling pathways has been shown to stimulate cell cycle re-entry in mature cardiomyocytes. In animal models of cardiac regeneration, various strategies have been used to target these pathways to stimulate cardiomyocyte renewal and have relied on the delivery of signaling factors via systemic delivery, epicardial patches, or direct intramyocardial injection. Gene therapy techniques involving the viral delivery of transgenes by using adenoviral or adeno-associated viral vectors have been used to successfully target cardiac gene expression. The delivery of nucleic acids in the form of anti-microRNAs and microRNA mimetics has also been shown to be effective in stimulating cardiomyocyte renewal. As the field of cardiac regeneration continues to progress, an important ongoing challenge in developing clinically translatable therapies is limiting the stimulation of growth pathways in non-cardiomyocytes.
PURPOSE OF REVIEW: Current pharmacologic treatments for cardiovascular disease do not correct the underlying cellular defect, the loss of cardiomyocytes. With recent advancements in cardiac regenerative approaches, the induction of endogenous mature cardiomyocyte proliferation has emerged as a new possibility. Here, we review progress made toward the regeneration of cardiac tissue in the mammalian heart through the stimulation of mature cardiomyocyte renewal. RECENT FINDINGS: The targeting of several developmental and signaling pathways has been shown to stimulate cell cycle re-entry in mature cardiomyocytes. In animal models of cardiac regeneration, various strategies have been used to target these pathways to stimulate cardiomyocyte renewal and have relied on the delivery of signaling factors via systemic delivery, epicardial patches, or direct intramyocardial injection. Gene therapy techniques involving the viral delivery of transgenes by using adenoviral or adeno-associated viral vectors have been used to successfully target cardiac gene expression. The delivery of nucleic acids in the form of anti-microRNAs and microRNA mimetics has also been shown to be effective in stimulating cardiomyocyte renewal. As the field of cardiac regeneration continues to progress, an important ongoing challenge in developing clinically translatable therapies is limiting the stimulation of growth pathways in non-cardiomyocytes.
Authors: Sohrab Fratz; Alfred Hager; Christian Schreiber; Markus Schwaiger; John Hess; Heiko C Stern Journal: Ann Thorac Surg Date: 2011-10-31 Impact factor: 4.330
Authors: Karl Toischer; Wuqiang Zhu; Mark Hünlich; Belal A Mohamed; Sara Khadjeh; Sean P Reuter; Katrin Schäfer; Deepak Ramanujam; Stefan Engelhardt; Loren J Field; Gerd Hasenfuss Journal: J Clin Invest Date: 2017-10-30 Impact factor: 14.808
Authors: Mei Xin; Yuri Kim; Lillian B Sutherland; Xiaoxia Qi; John McAnally; Robert J Schwartz; James A Richardson; Rhonda Bassel-Duby; Eric N Olson Journal: Sci Signal Date: 2011-10-25 Impact factor: 8.192
Authors: Shah R Ali; Simon Hippenmeyer; Lily V Saadat; Liqun Luo; Irving L Weissman; Reza Ardehali Journal: Proc Natl Acad Sci U S A Date: 2014-05-29 Impact factor: 11.205
Authors: Bernhard Kühn; Federica del Monte; Roger J Hajjar; Yuh-Shin Chang; Djamel Lebeche; Shima Arab; Mark T Keating Journal: Nat Med Date: 2007-07-15 Impact factor: 53.440
Authors: Mariya Mollova; Kevin Bersell; Stuart Walsh; Jainy Savla; Lala Tanmoy Das; Shin-Young Park; Leslie E Silberstein; Cristobal G Dos Remedios; Dionne Graham; Steven Colan; Bernhard Kühn Journal: Proc Natl Acad Sci U S A Date: 2013-01-09 Impact factor: 11.205
Authors: Zhiqiang Lin; Alexander von Gise; Pingzhu Zhou; Fei Gu; Qing Ma; Jianming Jiang; Allan L Yau; Jessica N Buck; Katryna A Gouin; Pim R R van Gorp; Bin Zhou; Jinghai Chen; Jonathan G Seidman; Da-Zhi Wang; William T Pu Journal: Circ Res Date: 2014-05-15 Impact factor: 17.367
Authors: Shijie Liu; Ke Li; Leonardo Wagner Florencio; Li Tang; Todd R Heallen; John P Leach; Yidan Wang; Francisco Grisanti; James T Willerson; Emerson C Perin; Sui Zhang; James F Martin Journal: Sci Transl Med Date: 2021-06-30 Impact factor: 19.319